Bridgeway Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Bridgeway Capital Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$301K	Hold	173,000	–	–	0.01%	934
2025 Q4	$301K	Buy	+173,000	New	+$381K	0.01%	934
2014 Q2	–	Sell	-625	Closed	-$100K	–	1445
2014 Q1	$100K	Hold	625	–	–	﹤0.01%	1386
2013 Q4	$87K	Hold	625	–	–	﹤0.01%	1361
2013 Q3	$62K	Buy	+625	New	+$52.4K	﹤0.01%	1403

Other funds holding INO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's INO Position: Q1 2026 in Review

Bridgeway Capital Management held its Inovio Pharmaceuticals (INO) position steady in Q1 2026 at 173,000 shares worth $301K. The position accounts for 0.01% of the portfolio, ranked #934.

Bridgeway Capital Management first reported a position in INO in Q3 2013 and has held it in 5 quarters since. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

Bridgeway Capital Management held 173,000 shares of Inovio Pharmaceuticals worth $301K as of Q1 2026.
Bridgeway Capital Management left its Inovio Pharmaceuticals share count unchanged in Q1 2026.
Inovio Pharmaceuticals made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #934 holding.
Bridgeway Capital Management first reported a position in Inovio Pharmaceuticals in Q3 2013 and has held it in 5 quarters since.
100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.